#1 Clinical Trials Search in Europe

Neratinib

Neratinib is an investigational drug being studied in various clinical trials for its potential in treating different types of cancer, particularly HER2-positive breast cancer. This article explores the ongoing research on Neratinib, its applications, and its effects on patients in clinical trial settings.

Table of Contents

What is Neratinib?

Neratinib is a medication used in the treatment of certain types of breast cancer. It’s also known by its brand names Nerlynx and HKI-272[1]. Neratinib belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which work by blocking specific proteins that contribute to cancer growth[2].

How Neratinib Works

Neratinib specifically targets the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a protein that, when present in high amounts, can cause breast cancer cells to grow and divide more quickly. By blocking HER2, Neratinib helps to slow down or stop the growth of cancer cells[3].

Conditions Treated with Neratinib

Neratinib is primarily used to treat HER2-positive breast cancer. This type of breast cancer has higher than normal levels of the HER2 protein on the surface of the cancer cells. Neratinib is used in various stages of HER2-positive breast cancer, including:

  • Early-stage breast cancer: Neratinib may be used as an extended adjuvant treatment. This means it’s given after initial treatment to help prevent the cancer from coming back[4].
  • Metastatic breast cancer: This is breast cancer that has spread to other parts of the body. Neratinib may be used in combination with other drugs to treat metastatic HER2-positive breast cancer[5].

How Neratinib is Administered

Neratinib is typically taken as an oral tablet once daily. The standard dose is usually 240 mg (often given as six 40 mg tablets) taken with food[1]. However, some studies are exploring different dosing strategies to manage side effects better:

  • Dose escalation: Starting with a lower dose and gradually increasing to the full dose over 2-4 weeks[4].
  • Combination therapy: Neratinib may be given alongside other cancer treatments, such as capecitabine or fulvestrant[5][3].

Neratinib in Clinical Trials

Neratinib has been and continues to be studied in various clinical trials. These trials aim to understand its effectiveness in different scenarios, optimal dosing strategies, and potential new applications. Some notable trials include:

  • Combining Neratinib with other drugs like Fulvestrant for metastatic breast cancer[3].
  • Using Neratinib after standard treatments to prevent cancer recurrence[4].
  • Exploring Neratinib’s potential in treating other types of cancer, such as metastatic prostate cancer[6].

Side Effects and Management

Like all medications, Neratinib can cause side effects. The most common and significant side effect is diarrhea. Other potential side effects may include nausea, abdominal pain, fatigue, vomiting, and rash[7].

To manage these side effects, especially diarrhea, doctors may:

  • Prescribe anti-diarrheal medications like loperamide[4].
  • Use a dose escalation strategy, starting with a lower dose and gradually increasing it[4].
  • Adjust the dose or temporarily stop treatment if side effects become severe.

Effectiveness of Neratinib

Clinical trials have shown that Neratinib can be effective in treating HER2-positive breast cancer. Some key findings include:

  • Improved invasive disease-free survival (iDFS) when used as extended adjuvant therapy in early-stage breast cancer[4].
  • Potential effectiveness in combination with other drugs for metastatic breast cancer[5].
  • Possible benefits in treating cancer that has spread to the brain (brain metastases)[5].

It’s important to note that the effectiveness of Neratinib can vary from person to person. Your doctor will consider various factors, including your specific type of cancer, previous treatments, and overall health, when deciding if Neratinib is right for you.

Aspect Details
Primary Focus HER2-positive breast cancer (early-stage and metastatic)
Other Cancers Studied Prostate cancer, solid tumors in children and young adults
Common Dosage 240 mg orally, once daily
Treatment Duration Typically up to 1 year in early-stage breast cancer trials
Main Side Effect Diarrhea
Key Research Areas Bioequivalence, dose escalation, combination with other therapies
Patient Populations Adults, children, and young adults with various cancers
Outcome Measures Invasive disease-free survival, overall survival, safety profile
Novel Approaches Dose escalation to manage side effects, use in combination with other anti-HER2 therapies

FAQ

  • What is Neratinib? Neratinib is an oral medication that belongs to a class of drugs called tyrosine kinase inhibitors. It specifically targets the HER2 protein, which is overexpressed in some types of cancer, particularly breast cancer.
  • What types of cancer is Neratinib being studied for? Neratinib is primarily being studied for HER2-positive breast cancer, both in early stages and metastatic settings. Some trials are also exploring its potential in other cancers like prostate cancer and solid tumors in children and young adults.
  • How is Neratinib administered in clinical trials? In most trials, Neratinib is administered orally, usually as a daily dose of 240 mg. Some studies are exploring different dosing regimens, including dose escalation approaches to manage side effects.
  • What are the common side effects of Neratinib? The most common side effect of Neratinib is diarrhea. Other potential side effects may include nausea, fatigue, and skin rashes. Many trials are investigating ways to manage these side effects, particularly diarrhea.
  • How long do patients typically take Neratinib in clinical trials? The duration of Neratinib treatment varies depending on the trial design. In many studies, particularly those for early-stage breast cancer, patients take Neratinib for up to one year. However, treatment duration can vary based on the specific trial protocol and patient response.

Ongoing Clinical Trials on Neratinib

  • Study on Maintenance Therapy with Cisplatin, Durvalumab, and Trastuzumab for Patients with Advanced Biliary Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France

  • Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Croatia France Italy Spain

Glossary

  • HER2: Human Epidermal growth factor Receptor 2, a protein that promotes the growth of cancer cells. When a breast cancer is HER2-positive, it means the cancer cells have too much of this protein.
  • Tyrosine kinase inhibitor: A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in many cell functions, including signaling, growth, and division.
  • Bioequivalence: The property wherein two drugs with identical active ingredients or two different dosage forms of the same drug possess similar bioavailability and produce the same effect at the site of physiological activity.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Castration-resistant prostate cancer: Prostate cancer that continues to grow even when the amount of testosterone in the body is reduced to very low levels.
  • Invasive disease-free survival: The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • ctDNA: Circulating tumor DNA, which are small fragments of DNA released by tumor cells into the bloodstream.

References

  1. https://clinicaltrials.gov/study/NCT00932464
  2. https://clinicaltrials.gov/study/NCT01111825
  3. https://clinicaltrials.gov/study/NCT04901299
  4. https://clinicaltrials.gov/study/NCT05154396
  5. https://clinicaltrials.gov/study/NCT01808573
  6. https://clinicaltrials.gov/study/NCT04781374
  7. https://clinicaltrials.gov/study/NCT05491057